Cargando…
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Hormone receptor (HR)(+) breast cancer (BC) causes most BC-related deaths, calling for improved therapeutic approaches. Despite expectations, immune checkpoint blockers (ICBs) are poorly active in patients with HR(+) BC, in part reflecting the lack of preclinical models that recapitulate disease pro...
Autores principales: | Buqué, Aitziber, Bloy, Norma, Perez-Lanzón, Maria, Iribarren, Kristina, Humeau, Juliette, Pol, Jonathan G., Levesque, Sarah, Mondragon, Laura, Yamazaki, Takahiro, Sato, Ai, Aranda, Fernando, Durand, Sylvère, Boissonnas, Alexandre, Fucikova, Jitka, Senovilla, Laura, Enot, David, Hensler, Michal, Kremer, Margerie, Stoll, Gautier, Hu, Yang, Massa, Chiara, Formenti, Silvia C., Seliger, Barbara, Elemento, Olivier, Spisek, Radek, André, Fabrice, Zitvogel, Laurence, Delaloge, Suzette, Kroemer, Guido, Galluzzi, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393498/ https://www.ncbi.nlm.nih.gov/pubmed/32732875 http://dx.doi.org/10.1038/s41467-020-17644-0 |
Ejemplares similares
-
Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
por: Buqué, Aitziber, et al.
Publicado: (2020) -
NK cells beat T cells at early breast cancer control
por: Buque, Aitziber, et al.
Publicado: (2020) -
Morphometric analysis of immunoselection against hyperploid cancer cells
por: Bloy, Norma, et al.
Publicado: (2015) -
Nicotinamide drives T cell activation in the mammary tumor microenvironment
por: Hu, Yang, et al.
Publicado: (2022) -
Trial Watch: Peptide-based anticancer vaccines
por: Pol, Jonathan, et al.
Publicado: (2015)